Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Pan Afr Med J ; 38: 183, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33995789

RESUMO

INTRODUCTION: the aim of our study is to determine, from data of the Moroccan register of biotherapies, the factors influencing the choice of the first prescribed biological treatment. METHODS: cross-sectional multicenter study including rheumatoid arthritis patients who were initiated the first biological treatment either: Rituximab, an anti-TNF, or Tocilizumab. The determinants related to the patient and disease have been gathered. A univariate and then multivariate analysis to determine the factors associated with the choice of the first bDMARDs was realized. RESULTS: a total of 225 rheumatoid arthritis patients were included in the Moroccan registry. The mean age was 52 ± 11 years, with female predominance 88% (n = 197). The first prescribed biological treatment was Rituximab 74% (n = 166), the second one was Tocilizumab, 13.6% (n = 31) then comes the anti-TNF in 3rd position with 12.4% (n = 28). The factors associated with the choice of Rituximab as the first line bDMARDs prescribed in univariate analysis were: the insurance type, the positivity of the rheumatoid factor. In multivariate analysis, only the insurance type that remains associated with the choice of Rituximab as the first biological drugs. The Tocilizumab was associated with shorter disease duration and was more prescribed as mono-therapy compared to non Tocilizumab group. TNFi was associated with the insurance type. CONCLUSION: our study suggests that Rituximab and TNFi are associated with the type of insurance and Tocilizumab is the most prescribed biologic mono-therapy in RA patients. Further studies are needed to confirm these results.


Assuntos
Anticorpos Monoclonais Humanizados/administração & dosagem , Antirreumáticos/administração & dosagem , Artrite Reumatoide/tratamento farmacológico , Rituximab/administração & dosagem , Adulto , Terapia Biológica/métodos , Estudos Transversais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Marrocos , Sistema de Registros , Estudos Retrospectivos , Fator de Necrose Tumoral alfa/antagonistas & inibidores
2.
Pan Afr Med J ; 34: 102, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31934245

RESUMO

Rheumatoid arthritis rarely involves the cricoarytenoid joint, symptoms of varying severity ranging from foreign body sensation, fullness or tension in the throat, hoarseness, odynophagia, speech or cough pain to stridor and respiratory distress during bilateral paralysis of the vocal cords. We are reporting a case of rheumatoid arthritis with bilateral involvement of the vocal cords. The diagnosis was clinically made and confirmed by endolaryngoscopy, responding to antirheumatic treatment but coming to the stage of permanent tracheotomy.


Assuntos
Artrite Reumatoide/complicações , Paralisia das Pregas Vocais/etiologia , Prega Vocal/patologia , Feminino , Humanos , Laringoscopia/métodos , Pessoa de Meia-Idade , Traqueotomia , Paralisia das Pregas Vocais/diagnóstico , Paralisia das Pregas Vocais/cirurgia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...